ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,061.48
      0.39%
      US Tech 100
      21,087.20
      0.52%
      Dow Jones
      44,873.28
      0.71%
      Brent Oil
      74.555
      -0.03%
      Bitcoin
      98,203.59
      1.64%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Caladrius Biosciences Inc (CLBS) Quote

      Caladrius Biosciences Inc

      Caladrius Biosciences Inc (CLBS)

      Celebrus Technologies Plc
      0.4264
      0.00
      (0.00%)
      Closed February 06 4:00PM
      Delayed by 15 minutes
      0.00
      0.00
      (0.00%)
      After Hours: -
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      0.4264
      Bid
      0.4264
      Ask
      0.43
      Volume
      -
      0.00 Day's Range 0.00
      0.00 52 Week Range 0.00
      Market Cap
      3.475M
      Previous Close
      0.4264
      Open
      -
      Last Trade
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      -
      Shares Outstanding
      8,150,000
      Dividend Yield
      -
      PE Ratio
      -1.02
      Earnings Per Share (EPS)
      -2.56
      Revenue
      -
      Net Profit
      -20.84M

      About Caladrius Biosciences Inc

      Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the... Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its current product candidates include XOWNA, HONEDRA and CLBS201. Show more

      Sector
      Health & Allied Services,nec
      Industry
      Insurance Carriers, Nec
      Website
      www.caladrius.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      2006

      Ask ADVFN Intelligence (AI)

      CLBS Latest News

      More News

      FeaturedVAYK Project $700K 2024 Revenue with $150K Net Profit

      14 hours ago

      Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

      Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens...

      September 15 2022
      GlobeNewswire Inc.

      Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

      BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified...

      September 14 2022
      GlobeNewswire Inc.

      Life Sciences Virtual Investor Conference Agenda Announced for September 15th

      NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual...

      September 12 2022
      GlobeNewswire Inc.

      Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022

      BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing...

      September 08 2022
      GlobeNewswire Inc.

      Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

      Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius’ initial...

      August 10 2022
      GlobeNewswire Inc.

      Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

      Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins...

      August 04 2022
      GlobeNewswire Inc.

      Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

      BASKING RIDGE, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

      August 02 2022
      GlobeNewswire Inc.

      Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time

      BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

      July 28 2022
      GlobeNewswire Inc.

      Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology

      BASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company...

      July 06 2022
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000CS
      40000000CS
      120000000CS
      260000000CS
      520000000CS
      1560000000CS
      2600000000CS

      CLBS - Frequently Asked Questions (FAQ)

      What is the current Caladrius Biosciences share price?
      The current share price of Caladrius Biosciences is $ 0.4264
      How many Caladrius Biosciences shares are in issue?
      Caladrius Biosciences has 8,150,000 shares in issue
      What is the market cap of Caladrius Biosciences?
      The market capitalisation of Caladrius Biosciences is USD 3.48M
      What is the 1 year trading range for Caladrius Biosciences share price?
      Caladrius Biosciences has traded in the range of $ 0.00 to $ 0.00 during the past year
      What is the PE ratio of Caladrius Biosciences?
      The price to earnings ratio of Caladrius Biosciences is -1.02
      What is the reporting currency for Caladrius Biosciences?
      Caladrius Biosciences reports financial results in USD
      What is the latest annual profit for Caladrius Biosciences?
      The latest annual profit of Caladrius Biosciences is USD -20.84M
      What is the registered address of Caladrius Biosciences?
      The registered address for Caladrius Biosciences is 651 N BROAD ST SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19709
      What is the Caladrius Biosciences website address?
      The website address for Caladrius Biosciences is www.caladrius.com
      Which industry sector does Caladrius Biosciences operate in?
      Caladrius Biosciences operates in the INSURANCE CARRIERS, NEC sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      RFACURF Acquisition Corporation
      $ 10.12
      (96.12%)
      		22.97k
      IVVDInvivyd Inc
      $ 2.1001
      (68.01%)
      		79.18M
      ASSTAsset Entities Inc
      $ 0.810001
      (47.46%)
      		170.15M
      ACBAurora Cannabis Inc
      $ 5.37
      (45.92%)
      		69.87M
      RNAZTransCode Therapeutics Inc
      $ 8.885
      (44.24%)
      		17.23M
      VLCNVolcon Inc
      $ 1.82
      (-43.13%)
      		3.88M
      CSAICloudastructure Inc
      $ 8.12
      (-37.44%)
      		250.67k
      CAPTCaptiVision Inc
      $ 0.6819
      (-35.06%)
      		8.88M
      LRHCLa Rosa Holdings Corporation
      $ 0.2695
      (-31.88%)
      		4.46M
      LYTLytus Technologies Holdings PTV Ltd
      $ 0.416999
      (-30.91%)
      		1.23M
      CYNCYNGN Inc
      $ 0.083
      (16.90%)
      		449.48M
      NVDANVIDIA Corporation
      $ 124.83
      (5.21%)
      		263.48M
      RIMEAlgorhythm Holdings Inc
      $ 0.0206
      (-15.57%)
      		238.29M
      ASSTAsset Entities Inc
      $ 0.810001
      (47.46%)
      		170.15M
      BHATBlue Hat Interactive Entertainment Technology
      $ 0.051599
      (17.81%)
      		143.98M

      Discussion

      View Full Feed
      Louinjaxxx Louinjaxxx 9 minutes ago
      Add into the mix, during the last 4-5 years, a pandemic, world-wide inflation, logistics delays, a war in Europe, etc, and you have unforeseen factors that would challenge major companies, much less a pink company.

      EXXEGroup is in much better shape than I would guess, 90% of pink shar
      AXXA
      otc37 otc37 11 minutes ago
      OTC markets shows vxit back to pink current. Maybe they have something to share this time around.
      VXIT
      sirant sirant 12 minutes ago
      Yes I believe the volume will go crazy today!!! JMHO 

      $MCIC TO PLUTO AND BEYOND 
      MCIC
      north40000 north40000 13 minutes ago
      Good thing that USPS changed its mind that it was NOT going to deliver packages imported from China or Hong Kong. The NOT version was an early news report on TV yesterday. The changed posture occurred later to "will". The oft overdosed fatal drug Fentanyl was the issue apparently--Fentanyl delivery
      BIEL
      PioneerPhoenix73 PioneerPhoenix73 14 minutes ago
      Analysis of Fractured Metal on the Titanic Ship

      The Titanic’s watery grave whispers a tale not of iceberg collisions, but of something far more sinister: the insidious Hutchison Effect! This post is dedicated to the materials scientists out there! This, my friends, is the real reason
      SINT
      thesmallguy thesmallguy 16 minutes ago
      Thank you for a non-emotional response and keeping the board civil. I also agree with this.
      ASII
      dutchfree dutchfree 17 minutes ago
      I'm never going anywhere! I just stay here.... why will you exit when predicted profits will show up???
      NB
      knrorrel knrorrel 23 minutes ago
      $HCAI here looks , on watch 🚀🚀🚀 https://x.com/madking270/status/1887299740338983325?t=Pw5wIjxOhlRATtADEo-W9A&s=09

      HCAI
      knrorrel knrorrel 25 minutes ago
      $HCAI here looks , on watch 🚀🚀🚀 https://x.com/madking270/status/1887299740338983325?t=Pw5wIjxOhlRATtADEo-W9A&s=09


      HCAI
      Panzer Panzer 27 minutes ago
      Same
      RITE
      sirant sirant 32 minutes ago
      MCIC - Multicorp International, Inc. | Security Details | OTC Markets
      https://www.otcmarkets.com/stock/MCIC/security

      GO $MCIC 
      MCIC
      Genz2 Genz2 47 minutes ago
      Wave’s phone number is: 1-800-928-3638 and I believe ESW Holdings Inc.’s (Wave) CEO Steven K. SPRAGUE’s number is (413)-698-4275!! The CEO of Crowdstrike has his degree in accounting and Steven has his degree in mechanical engineering!! I’m sorry, but if I was an organization that wanted better c
      Elroy Jetson Elroy Jetson 52 minutes ago
      Trump throws out the term "the new golden age", a color his insecure nature is drawn to - but it's a gilded age, just like the prior gilded age of the 1870s to 1890s.

      Gilded is a golden color or a thin layer of gold covering up something far different, something you're tying to hide a
      rocketeer357 rocketeer357 54 minutes ago
      My GM has certainly bailed out the foundering Mets ship in short order. Less than 2 years on the job and you have a team that should compete deep into the post-season for the next 10 years, barring injuries.
      After all those Wilpon/Brodie/Eppler years, the present and the future look pretty f
      north40000 north40000 54 minutes ago
      Kindly provide a link for your statement that "official "volume" includes buys AND sells, so it's 500,000 shares that traded hands."  If I sell one million shares of  XXXX, some person(s) buy one million shares of XXXX when transaction is completed.  One million shares have changed ownership---that
      AMRN
      weedtrader420 weedtrader420 54 minutes ago
      BITCOIN XRP Here comes the Sun☀️ 🖕👀🖕$120,000 target
      BTCUSD
      joeycav11 joeycav11 55 minutes ago
      200k is cheap in comparison to other expensive biologics with side effects and less efficacy.
      What if dcvax is approved based on rwe from addition of polyicl and evidence from the special’s program thats been ongoing…
      Along with the clinical trials comparing dcvav and poly and dcvax
      NWBO
      weedtrader420 weedtrader420 56 minutes ago
      DOGECOINX $1 TARGET
      DOGEUSD
      DTGoody DTGoody 58 minutes ago
      Trump & the THIRD TEMPLE 2025: End Times SECRET Construction & Israel’s Red Heifers

      https://youtu.be/jbh5lxSxFO4
      littlejohn littlejohn 1 hour ago
      Natural gas seems due to plummet with China

      out of buying market now...

      Nat gas drillers already shut in wells

      last year to slow production...

      So, companies didn't need the rift with

      China that was started...

      T
      NorCalTommy NorCalTommy 1 hour ago
      Hate to be a buzz-kill but I'm having a hard time getting excited when we are still almost $5 DOLLARS BELOW the SP before all of this SPAC/Reverse Merger Management Hail Mary...... we still have about 300% to go before we just break even and dig ourselves out of the hole that management dug for us
      NB
      janice shell janice shell 1 hour ago
      This is... Surprising:

      https://x.com/gunsnrosesgirl3/status/1887382797490454782

      Your Recent History

      NASDAQ
      CLBS
      Caladrius Biosciences
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads